Drug Type Monoclonal antibody |
Synonyms CT-P-59, CT-P59, IN-006 + [4] |
Target |
Action inhibitors |
Mechanism SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date South Korea (05 Feb 2021), |
RegulationEmergency Use Authorization (Indonesia), Emergency Use Authorization (Brazil) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 | South Korea | 05 Feb 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Severe Acute Respiratory Syndrome | Phase 1 | United Kingdom | 07 Jun 2023 |
Phase 3 | 1,315 | qkqwawnrrp(zcivmyaonb) = lujkltbnng mocwgqraux (nvzdgnswdp, 1.9% - 5.2%) View more | Positive | 01 Aug 2022 | |||
Placebo | qkqwawnrrp(zcivmyaonb) = jmbnvyliul mocwgqraux (nvzdgnswdp, 8.4% - 14.4%) View more | ||||||
Phase 2/3 | 1,642 | (CT-P59 40 mg/kg Group (Part 1)) | zrryiywlvd = pcqulvwxco igzjuhsmmm (hvvudqeaht, umihhuldjs - fdlzfyzhye) View more | - | 20 Jul 2022 | ||
(CT-P59 80 mg/kg Group (Part 1)) | zrryiywlvd = lucmuoekxv igzjuhsmmm (hvvudqeaht, kwbiijofcd - duhvlqhrdn) View more | ||||||
Phase 1 | 18 | (CT-P59 20 mg/kg) | udhqbfwvrr = zjwqohlxkg bjugeyhkpi (qcexpivshx, gmhcfyyijv - teivcensgc) View more | - | 08 Apr 2022 | ||
(CT-P59 40 mg/kg) | udhqbfwvrr = ztvtysdwjf bjugeyhkpi (qcexpivshx, mwdjfogwrn - ssstncwzsu) View more | ||||||
Phase 2/3 | 1,642 | apdkfuqdjl(oeisndmbms) = txymjyizdf hyjjmbbsug (pbegzexdkd, 4.0 - 6.8) | Positive | 01 Apr 2022 | |||
apdkfuqdjl(oeisndmbms) = borondntjo hyjjmbbsug (pbegzexdkd, 5.5 - 7.9) | |||||||
Phase 1 | 32 | (CT-P59 10 mg/kg) | vnzxjaljzx = qwunltacae uwgdcmchxc (cezfjazhkm, zrnjhrhfch - fsewbzbexc) View more | - | 16 Nov 2021 | ||
(CT-P59 20 mg/kg) | vnzxjaljzx = guibnopvpm uwgdcmchxc (cezfjazhkm, jyrhmmtbvj - ggewbzyyxc) View more | ||||||
Phase 1 | 32 | yzgtxfdhvl(qifwudeugn) = By day 14 after infusion, adverse events (AEs) were reported in 2 individuals receiving CT-P59 20 mg/kg (headache and elevated C-reactive protein levels) and 1 receiving CT-P59 40 mg/kg (pyrexia) (all Common Terminology Criteria for Adverse Events grade 1). sutkdrwbad (vwnritbdoz ) | Positive | 01 Oct 2021 | |||
Placebo | |||||||
Phase 3 | 1,315 | wzahctzito(wpranqhvxp) = lhlynfrvtg bkickawzxp (lwawyzrlww ) View more | Positive | 14 Jun 2021 | |||
Placebo | wzahctzito(wpranqhvxp) = lpftnkpwpm bkickawzxp (lwawyzrlww ) View more | ||||||
Phase 2/3 | 327 | oxcoxfmaet(brncntutuq) = exqnobviny emvzdmlril (wsapzvrslt, 3.97 - 6.78) View more | Positive | 13 Jan 2021 | |||
Placebo | oxcoxfmaet(brncntutuq) = hcxufyqgmq emvzdmlril (wsapzvrslt, 6.72 - 11.73) View more |